Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Home/
      2. Our innovation /
      3. Focus areas/
      4. Immunology/
      5. Supporting Patients on World Lupus Day

      Janssen Showcases Support for Patients This World Lupus Day

      Supporting Patients on World Lupus Day and Every Day

      Share Article
      Share to

      On May 10, we recognize World Lupus Day by remaining committed to deepening our understanding of lupus, a complex and often misdiagnosed disease affecting more than five million people worldwide.

      Lupus can affect any part of the body and is difficult to manage, with only one treatment approved in the last 60 years. At Janssen, we understand the impact a diagnosis of lupus has on a person, and we are focused on advancing new therapies that may provide options for patients in the future. As we set on an exciting and new trajectory in lupus research, our scientists are collaborating with global researchers, healthcare providers, academics and patient organizations to progress the science and treatment for lupus patients around the world.

      This World Lupus Day we take a moment to honor all of those impacted by lupus as we continue our mission to Reshape the Future of Immunology. Follow our efforts to raise awareness on Janssen Global social channels using #WorldLupusDay.

      world_lupus_day_blog_050918.jpg

      Dan Baker, M.D.
      Dan Baker, M.D.
      Dan Baker, M.D.
      Dan Baker, M.D. joined Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, through Centocor Research & Development in 2000 following an 18-year academic career at the University of Pennsylvania in Philadelphia, Pennsylvania. Since joining Janssen, he has held key roles in the clinical development of the industry-leading Janssen immunology portfolio for a plethora of indications. Dan is a board-certified rheumatologist and as Disease Area Leader for Rheumatoid Arthritis (RA), he is responsible for leading a cross-functional team of experts to outline near- and long-term, prioritized scientific and business strategies with the goal of maintaining industry leadership in RA.
      Pearl Pugh
      Pearl Pugh
      Pearl Pugh
      Pearl Pugh, Disease Area Commercial Leader, is responsible for developing and executing the end-to-end strategy for the Rheumatology and Psoriasis Disease Areas. Pearl also provides leadership to global commercial teams to ensure effective partnerships with cross-functional and regional stakeholders for worldwide launch readiness of new products and line extensions, and to maximize current in-market assets worldwide. Prior to joining Janssen Immunology, Pearl was the Director of Marketing, Prostate, at Janssen Oncology US.